Merck (MRK) reported $15.81 billion in revenue for the quarter ended June 2025, representing a year-over-year decline of 1.9%. EPS of $2.13 for the same period compares to $2.28 a year ago.
The reported revenue represents a surprise of -0.02% over the Zacks Consensus Estimate of $15.81 billion. With the consensus EPS estimate being $2.01, the EPS surprise was +5.97%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Merck performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Sales- Oncology- Keytruda - U.S.: $4.75 billion versus the four-analyst average estimate of $4.67 billion. The reported number represents a year-over-year change of +7.6%.
- Sales- Oncology- Keytruda - International: $3.21 billion compared to the $3.16 billion average estimate based on four analysts. The reported number represents a change of +12.2% year over year.
- Sales- Diabetes- Janumet - U.S.: $68 million compared to the $45.63 million average estimate based on three analysts. The reported number represents a change of +300% year over year.
- Sales- Oncology- Alliance revenue- Lynparza - U.S.: $174 million versus the three-analyst average estimate of $140.82 million. The reported number represents a year-over-year change of +13.7%.
- Sales- Oncology- Alliance Revenue- Lynparza: $370 million compared to the $321.44 million average estimate based on four analysts. The reported number represents a change of +16.7% year over year.
- Sales-Cardiovascular-Winrevair: $336 million versus the four-analyst average estimate of $343.79 million.
- Sales- Oncology- Alliance revenue- Lenvima: $265 million versus $244.01 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +6.4% change.
- Sales- Oncology- Keytruda: $7.96 billion compared to the $7.9 billion average estimate based on four analysts. The reported number represents a change of +9.4% year over year.
- Sales- Animal health: $1.65 billion versus $1.55 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +11.1% change.
- Sales- Vaccines- Gardasil: $1.13 billion compared to the $1.3 billion average estimate based on four analysts. The reported number represents a change of -54.6% year over year.
- Sales- Oncology- Welireg: $162 million versus $154.16 million estimated by four analysts on average.
- Sales- Virology- Lagevrio: $83 million versus $55.63 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -24.6% change.
View all Key Company Metrics for Merck here>>>
Shares of Merck have returned +6.2% over the past month versus the Zacks S&P 500 composite's +3.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Merck & Co., Inc. (MRK): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
